From Quantification to Differentiation: T2 Mapping for Mucinous Components in Primary and Post-neoadjuvant Rectal Cancers

Rectal cancer is a serious disease where abnormal cells grow in the last part of the large intestine. Among the many types of this cancer, a specific variety called mucinous adenocarcinoma behaves differently from the rest. In this type, the tumor produces a large amount of a slippery, jelly-like substance known as mucin. This substance acts like a physical shield, often making the cancer harder to treat with radiation and chemotherapy compared to other forms. Doctors need to know exactly how much of this jelly-like material is present before they start treatment, because a high amount suggests the cancer might be more aggressive and require a different approach.

The challenge is that while this mucin is easy to see under a microscope after surgery, it is very difficult to measure before the operation. Standard magnetic resonance imaging, or MRI, shows both the cancer cells and the mucin as bright white areas, making them look almost identical. This creates a confusing situation for doctors: they cannot easily tell if a bright spot on the scan is a dangerous tumor full of cells, or if it is a sign that treatment is working and the tumor has turned into mostly harmless jelly. Without a clear way to distinguish between these two possibilities, patients might undergo unnecessary major surgery or, conversely, miss the chance for a less invasive treatment.

Researchers at the First Affiliated Hospital of Shandong First Medical University set out to solve this problem by using a specialized version of MRI called T2 mapping. Unlike standard MRI, which produces a simple black-and-white picture, T2 mapping measures the specific time it takes for water molecules within the tissue to relax after being stimulated by the machine. Because the jelly-like mucin holds water in a unique way, it changes this relaxation time. The team wanted to see if they could use these time measurements to count the amount of mucin in a tumor and to tell the difference between a primary tumor and one that had changed after treatment.

The researchers looked back at medical records from patients who had surgery for rectal cancer between 2021 and 2025. They divided their work into two parts. First, they examined 55 patients to see if the T2 mapping numbers matched the actual amount of mucin found in the lab after surgery. They categorized the tumors into three groups: those with no mucin, those with some mucin but less than half the tumor volume, and those where mucin made up more than half. The results were striking. The more mucin the tumor contained, the longer the relaxation time measured by the MRI. The tumors with no mucin had an average time of about 82 milliseconds, those with a small amount of mucin averaged around 93 milliseconds, and the tumors dominated by mucin averaged 161 milliseconds. This strong link meant the machine could effectively act as a scale, weighing the amount of jelly inside the tumor without cutting it open.

In the second part of the study, the team focused on a specific clinical dilemma involving 27 patients. Some of these patients had received radiation and chemotherapy before surgery, and their scans showed bright areas that looked like mucin. The doctors needed to know if this was a sign that the treatment had worked, turning the tumor into harmless, cell-free jelly, or if it was a stubborn, original mucin-rich cancer that had survived. The T2 mapping provided a strong indication to help distinguish these conditions. The harmless, treatment-induced jelly had a longer relaxation time, averaging 199 milliseconds, while the dangerous, original cancer averaged 156 milliseconds. The researchers found that if the measurement was above 182 milliseconds, it was more likely to be the harmless, treated tissue, whereas values below that suggested the presence of the original, active cancer. However, this distinction was not absolute; the method achieved a diagnostic accuracy (AUC) of 0.825 with a sensitivity of 83% and specificity of 80%, meaning there was still some overlap where the two conditions could look similar.

To ensure these findings were reliable and not just a lucky match with their specific group of patients, the researchers tested their results by leaving out one patient at a time and recalculating the numbers. This process confirmed that the thresholds they found were stable. For instance, the point that separated harmless treated tissue from dangerous cancer remained consistent, hovering just around 188 milliseconds in these repeated tests. The study also identified where the method might fail. In a few cases, tumors without mucin were mistaken for having some because of swelling or fluid from inflammation, which also lengthened the relaxation time. Conversely, some treated tumors that still contained a few stubborn cells or fibrous tissue were mistaken for dangerous cancer because those elements shortened the relaxation time. These exceptions show that while the tool is powerful, it is not perfect and works best when combined with a doctor's careful review of the images.

This research suggests that T2 mapping can serve as a precise, non-invasive tool for doctors to understand the hidden composition of rectal tumors. By quantifying the amount of mucin and distinguishing between active cancer and treatment-induced changes, this technique offers a way to tailor treatment plans more accurately. Patients with high mucin content might be steered toward more aggressive therapies, while those showing signs of harmless degeneration after treatment might be candidates for less invasive surgery. While these results are promising, the authors note that the study was conducted at a single hospital with a limited number of patients, so further testing with larger groups is needed before this method becomes a standard part of medical care.